News | Heart Valve Technology | August 22, 2017

CMS Awards New Technology Add-on Payment for Perceval Sutureless Aortic Heart Valve

Hospitals will receive an additional payment up to $6,110.23 beginning Oct. 1

CMS Awards New Technology Add-on Payment for Perceval Sutureless Aortic Heart Valve

August 22, 2017 — LivaNova PLC announced its Perceval sutureless aortic heart valve received approval from the Centers for Medicare and Medicaid Services (CMS) for a New Technology Add-on Payment (NTAP). The Perceval valve met the CMS criteria for NTAP, including the demonstration of substantial clinical improvement over existing technologies. Beginning on Oct. 1, 2017, CMS has stated it will reimburse hospitals for the Perceval valve procedure with the Medicare Severity Diagnosis Related Group (MS-DRG) payment they normally receive, plus an additional payment of up to $6,110.23.

Clinical trial data has demonstrated the Perceval valve’s ability to optimize the overall surgical approach for cardiac surgeons through reduced procedure times, decreased postoperative complications and shorter hospital stays. The Perceval valve is suitable for traditional surgery and also enables minimally invasive surgical approaches through its collapsible design and sutureless deployment. Engineered to restore natural valve performance, the Perceval valve features a super-elastic stent, which is able to adapt to the movement of the aorta during the cardiac cycle and provide excellent hemodynamics.

Perceval received U.S. Food and Drug Administration (FDA) approval in 2016, but has been in clinical use worldwide for 10 years and studied in more than 190 publications. Severe aortic stenosis affects over 500,000 Americans and 85,000 patients undergo aortic valve replacement each year.

Read the article "LivaNova Announces Positive Data for Perceval Sutureless Valve at AATS 2017."

Read the artcile "Practice Completes First Implant of Perceval S Self-Anchoring Aortic Heart Valve in Texas."

For more information: www.livanova.com

Related Content

Montreal Heart Institute Performs First Robotic Mitral Valve Surgery
News | Robotic Systems| September 22, 2017
The Montreal Heart Institute (MHI) announced the acquisition of the da Vinci Xi, a new-generation surgical robot, and...
Edwards Inspiris Resilia Valve Receives FDA Approval
News | Heart Valve Technology| September 21, 2017
Edwards Lifesciences Corp. recently received U.S. Food and Drug Administration (FDA) approval for its Inspiris Resilia...
DISRUPT BTK Study Shows Positive Results With Lithoplasty in Calcified Lesions Below the Knee
News | Peripheral Artery Disease (PAD)| September 20, 2017
Shockwave Medical reported positive results from the DISRUPT BTK Study, which were presented at the annual...
Gecko Biomedical Receives CE Mark Approval for Setalum Sealant
News | Cardiovascular Surgery| September 19, 2017
Gecko Biomedical announced it has received CE Mark approval for its Setalum Sealant, allowing the company to market its...
Sentinel Cerebral Protection System Significantly Reduces Stroke and Mortality in TAVR
News | Embolic Protection Devices| September 18, 2017
September 18, 2017 – Claret Medical announced publication of a new study in the...
Sponsored Content | Videos | Structural Heart Occluders| September 13, 2017
Ziyad Hijazi, M.D., MPH, MSCAI, FACC, director of the cardiac program and chair of the Department of Pediatrics at Si
Cardiovascular Research Foundation (CRF) announced the promotion of Juan F. Granada, M.D., as the foundation’s president and chief executive officer (CEO). CRF sponsors TCT.

The Cardiovascular Research Foundation (CRF) announced the promotion of Juan F. Granada, M.D., as the foundation’s president and chief executive officer (CEO).

Feature | Cath Lab| September 12, 2017
September 12, 2017 – The Cardiovascular Research Foundation (CRF) a
TCT 2017 late-breaking trials and studies that will be presented on the latest cardiology technology clinical trials.
Feature | September 11, 2017
September 11, 2017 — From numerous high-quality submissions, Transcatheter Cardiovascular Therapeutics (TCT) has sele
ClearFlow Inc. Announces Positive U.S. Clinical Trial Results
News | Cardiovascular Surgery| September 08, 2017
September 8, 2017 — ClearFlow Inc.
Abbott will end sales of the Absorb bioresorbable stent scaffold, pulling it off the market September 14, 2017.
Feature | Stents Bioresorbable| September 08, 2017 | Dave Fornell
September 8, 2017 — Abbott Vascular has announced it will end commercial sales of its Absorb bioresorbable vascular s
Overlay Init